Get more replies from employers
Send a job-specific resume in minutes.
Abiologics, Inc. in Boston is seeking a motivated cell biologist and assay developer to join their Pharmacology team. The successful candidate will design and execute assays to assess Syntein activity and support their growing pipeline.
Requirements include a PhD in molecular or cell biology, technical expertise in cell culture, and strong assay development skills. Benefits include healthcare and a competitive salary range of $100,000 – $126,500.
Abiologics, Inc. is a privately held, early‑stage biotechnology company on a mission to make biology better through an innovative therapeutic modality. We are pioneering the development of Synteins, a transformational class of macromolecular medicines unlocked by novel synthetic and computational technologies.
We are looking for a highly motivated, broadly skilled cell biologist and assay developer to join our growing Pharmacology team. In this role, the successful candidate will be responsible for developing and executing biochemical and cell‑based assays to support the progression of Abiologics’ pipeline. Occasionally, this individual may contribute to in vivo and ex‑vivo pharmacology activities to progress projects and the platform. The role will collaborate cross‑functionally with a diverse design‑make‑test team across Abiologics and have the opportunity to impact platform and company growth.
We are an equal‑opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other characteristic protected by law.
The salary range for this role is $100,000 – $126,500. Abiologics, Inc. currently offers health care coverage, an annual incentive program, retirement benefits, and a broad range of other benefits. Compensation and benefits information are based on Abiologics’ good‑faith estimate as of the date of publication and may be modified in the future.